Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Panithaya Chareonthaitawee, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01370265
First received: June 6, 2011
Last updated: September 3, 2013
Last verified: September 2013

June 6, 2011
September 3, 2013
February 2011
February 2012   (final data collection date for primary outcome measure)
Global Hyperemic Myocardial Blood Flow (MBF) [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ] [ Designated as safety issue: No ]

MBF is the rate of blood supplied to the myocardium, or heart muscle. Hyperemic MBF is the rate of myocardial blood flow in the heart muscle during either regadenoson or adenosine stress. Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).

The Hyperemic MBF was measured approximately 4 hours after arrival in the PET unit.

Myocardial blood flow (MBF) [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
To quantify regadenoson-induced hyperemic PET N-13 ammonia MBF and compare to adenosine-induced hyperemic PET N-13 ammonia MBF.
Complete list of historical versions of study NCT01370265 on ClinicalTrials.gov Archive Site
  • Resting Global MBF and Resting Segmental MBF [ Time Frame: Day 2, approximately 35 minutes after arrival in positron emission tomography (PET) unit ] [ Designated as safety issue: No ]

    MBF is the rate of blood supplied to the myocardium, or heart muscle. Global Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).

    Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes.

  • Global Cardiac Flow Rate [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ] [ Designated as safety issue: No ]
    Cardiac Flow Rate was calculated using the equation: hyperemic MBF/resting MBF.
  • Hyperemic Segmental MBF [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ] [ Designated as safety issue: No ]

    Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes.

    The hyperemic MBF was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.

  • Segmental CFR [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ] [ Designated as safety issue: No ]
    CFR was calculated using the equation: hyperemic MBF/resting MBF.
  • Heart Rate (Beats Per Minute (BPM)) [ Time Frame: Day 2, approximately 35 minutes and approximately 4 hours after arrival in the PET unit ] [ Designated as safety issue: No ]
    The resting heart rate was measured approximately 35 minutes after arrival in the PET unit. The hyperemic heart rate was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.
  • Hyperemic Blood Pressure (mmHg) [ Time Frame: Day 2, approximately 4 hours after arrival in the PET unit ] [ Designated as safety issue: No ]
    Blood pressure was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.
Not Provided
Not Provided
Not Provided
 
Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress

Blockage of the heart arteries (coronary artery disease) can lead to angina (chest pain), heart attacks, heart failure, and/or death. Positron emission tomography (PET) stress myocardial perfusion imaging (MPI) is a powerful tool to help identify blockages in the coronary arteries. During the PET MPI test, a drug is given to mimic the effects of exercise on the heart. The study was done to measure blood flow to the heart using two similar drugs approved to mimic the effects of exercise on the heart in people during a heart stress test. The first drug, called adenosine, has been approved for this use for several decades. The second drug, called regadenoson, was approved in 2008. The investigators were looking at whether the increase in blood flow to the heart with the newer drug (regadenoson) was similar to the increase in blood flow with the older drug (adenosine). This information is important for the use of these drugs in patients and for interpreting the blood flow values.

The hypothesis for this study was that Regadenoson will produce a very similar degree of maximal hyperemia (increased blood flow) as adenosine, the other vasodilator agent. There were only 2 days on study for each subject.

On Day 1 of the study, subjects were interviewed and had a physical exam, including a resting 12-lead electrocardiogram (ECG) to exclude evidence of silent ischemia or myocardial infarction, and other cardiovascular disorders. Subjects were instructed to have a light meal at least 4 hours prior to the PET MPI. Subjects were instructed to abstain from caffeine-containing products for 24 hours prior to the PET scan. Day 1 of the study occurred less than or equal to 4 weeks of Day 2.

On Day 2 of the study, each subject underwent three PET N-13 ammonia (10-20 mCi) dynamic emission acquisitions: resting, regadenoson (0.4 mg/5 mL IV), and adenosine (140 microgram/kg/min; order of regadenoson vs adenosine was randomized according to subject's birth year), and three transmission acquisitions for attenuation correction. Each emission acquisition was separated by 50 min to allow for radioactive decay. At the end of the drug infusions, subjects were monitored for 5-30 min. Based on the known short biological half-lives of these stress agents, the pharmacologic effects of each drug should have dissipated by the time the next drug was administered.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Coronary Artery Disease
  • Drug: Regadenoson
    Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
    Other Name: Lexiscan
  • Drug: Adenosine
    Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
    Other Name: Adenoscan
  • Drug: N-13 ammonia
    Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
  • Active Comparator: Regadenoson, then Adenosine
    Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
    Interventions:
    • Drug: Regadenoson
    • Drug: Adenosine
    • Drug: N-13 ammonia
  • Active Comparator: Adenosine, then Regadenoson
    Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
    Interventions:
    • Drug: Regadenoson
    • Drug: Adenosine
    • Drug: N-13 ammonia
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
June 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and female volunteers over the age of 30.
  • Written informed consent will be obtained from each subject.
  • Each subject will undergo a history and physical examination

Exclusion Criteria:

  • Any cardiovascular or pulmonary symptoms or exam findings
  • History of low blood pressure (< 90/50 mmHg)
  • Prior cardiac history
  • History of hypertension
  • History of hyperlipidemia
  • History of diabetes mellitus
  • History of asthma or chronic obstructive pulmonary disease
  • Weight of > 450 pounds
  • Chronic kidney disease
  • Other serious illness such as cancer
  • Current smoking
  • Medication use (with the exception of acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and thyroid hormone replacement)
  • Illicit drug use
  • Prior allergic reaction to adenosine, regadenoson, or aminophylline
  • Pregnancy
Both
30 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01370265
10-006377
No
Panithaya Chareonthaitawee, Mayo Clinic
Mayo Clinic
Astellas Pharma Inc
Principal Investigator: Panithaya Chareonthaitawee, M.D. Mayo Clinic
Mayo Clinic
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP